T.-Y. Kim

871 total citations
19 papers, 406 citations indexed

About

T.-Y. Kim is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, T.-Y. Kim has authored 19 papers receiving a total of 406 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 7 papers in Hepatology. Recurrent topics in T.-Y. Kim's work include Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Colorectal Cancer Treatments and Studies (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). T.-Y. Kim is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Colorectal Cancer Treatments and Studies (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). T.-Y. Kim collaborates with scholars based in South Korea, United States and Japan. T.-Y. Kim's co-authors include Masatoshi Kudo, Wendy Verret, Sairy Hernandez, S. Mulla, Philippe Merle, В. В. Бредер, Chen Huang, Ann‐Lii Cheng, Zhen Xu and Ahmed O. Kaseb and has published in prestigious journals such as Annals of Oncology, International Journal of Solids and Structures and Clinical Radiology.

In The Last Decade

T.-Y. Kim

19 papers receiving 399 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
T.-Y. Kim South Korea	8	210	126	125	87	74	19	406
Claudio Chini Italy	8	107 0.5×	57 0.5×	175 1.4×	116 1.3×	135 1.8×	21	342
Wataru Takayama Japan	13	265 1.3×	100 0.8×	170 1.4×	218 2.5×	19 0.3×	51	513
Barbara M. Zonderhuis Netherlands	11	211 1.0×	37 0.3×	116 0.9×	227 2.6×	145 2.0×	27	556
Theo Ruers Netherlands	10	460 2.2×	372 3.0×	153 1.2×	189 2.2×	34 0.5×	13	606
Diederik J. Höppener Netherlands	13	337 1.6×	298 2.4×	77 0.6×	94 1.1×	20 0.3×	26	494
Yangkui Gu China	11	130 0.6×	169 1.3×	154 1.2×	137 1.6×	53 0.7×	25	425
Ariel E. Birnbaum United States	8	118 0.6×	24 0.2×	119 1.0×	60 0.7×	22 0.3×	25	284
Silvia Girolama Drago Italy	9	252 1.2×	46 0.4×	187 1.5×	84 1.0×	10 0.1×	16	623
Stephanie K. Schaub United States	12	124 0.6×	203 1.6×	204 1.6×	99 1.1×	29 0.4×	48	516
Naoki Ishiwa Japan	11	152 0.7×	17 0.1×	173 1.4×	125 1.4×	52 0.7×	27	424

Countries citing papers authored by T.-Y. Kim

Since Specialization

Citations

This map shows the geographic impact of T.-Y. Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T.-Y. Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T.-Y. Kim more than expected).

Fields of papers citing papers by T.-Y. Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T.-Y. Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T.-Y. Kim. The network helps show where T.-Y. Kim may publish in the future.

Co-authorship network of co-authors of T.-Y. Kim

This figure shows the co-authorship network connecting the top 25 collaborators of T.-Y. Kim. A scholar is included among the top collaborators of T.-Y. Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T.-Y. Kim. T.-Y. Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Kim, T.-Y., Yoonjin Kwak, Soo Kyung Nam, et al.. (2024). Clinicopathological analysis of claudin 18.2 focusing on intratumoral heterogeneity and survival in patients with metastatic or unresectable gastric cancer. ESMO Open. 9(12). 104000–104000. 8 indexed citations

Kim, T.-Y., S.Y. Kim, Jihun Kim, et al.. (2024). Nationwide precision oncology pilot study: KOrean Precision Medicine Networking Group Study of MOlecular profiling-guided therapy based on genomic alterations in advanced solid tumors (KOSMOS) KCSG AL-20-05. ESMO Open. 9(10). 103709–103709. 1 indexed citations

El-Khoueiry, Anthony B., Jörg Trojan, Tim Meyer, et al.. (2023). Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040. Annals of Oncology. 35(4). 381–391. 27 indexed citations

Lee, Dong Hun, et al.. (2021). Shear-wave velocity for colorectal cancer liver metastases as a potential prognostic factor after chemotherapy: a preliminary study. Clinical Radiology. 76(3). 224–232. 2 indexed citations

Kim, T.-Y., et al.. (2019). The analysis of T cell subsets and clinical efficacy of immune checkpoint blockades in patients with advanced gastric cancer using multiplex immunohistochemistry. Annals of Oncology. 30. v313–v313. 1 indexed citations

Cheng, Ann‐Lii, Masafumi Ikeda, Peter R. Galle, et al.. (2019). IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). Annals of Oncology. 30. ix186–ix187. 150 indexed citations

Qin, Shukui, Ann‐Lii Cheng, Michel Ducreux, et al.. (2018). IMbrave150: A randomised phase III study of atezolizumab + bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma. Annals of Oncology. 29. ix66–ix66. 3 indexed citations

Ryoo, Baek‐Yeol, Zhenggang Ren, T.-Y. Kim, et al.. (2018). Phase II trial of tepotinib vs sorafenib for treatment-naïve advanced hepatocellular carcinoma (HCC) in Asian patients. Annals of Oncology. 29. ix58–ix59. 1 indexed citations

Ducreux, Michel, Ann‐Lii Cheng, Shukui Qin, et al.. (2018). Atezolizumab + bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma: The randomised phase III study IMbrave150. Annals of Oncology. 29. viii267–viii267. 4 indexed citations

10.

Lee, K.-W., Byung Woog Kang, Ick‐Joong Chung, et al.. (2018). Treatment patterns and changes in quality of life during first-line palliative chemotherapy in Korean patients with advanced gastric cancer. Annals of Oncology. 29. viii228–viii228. 5 indexed citations

11.

Schiffer, Andreas, et al.. (2017). Interaction of highly nonlinear solitary waves with elastic solids containing a spherical void. International Journal of Solids and Structures. 118-119. 204–212. 35 indexed citations

12.

Al‐Batran, Salah‐Eddin, Eric Van Cutsem, Sang Cheul Oh, et al.. (2016). Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology. 27(4). 673–679. 55 indexed citations

13.

Melero, Ignacio, Bruno Sangro, Tung On Yau, et al.. (2016). 219O Safety and preliminary efficacy of nivolumab in patients with advanced hepatocellular carcinoma: interim analysis of the phase 1/2 CheckMate-040 study. Annals of Oncology. 27. ix68–ix69. 4 indexed citations

14.

An, Eunkyung, Chan‐Young Ock, T.-Y. Kim, et al.. (2016). Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment. Annals of Oncology. 28(1). 110–115. 32 indexed citations

15.

Melero, Ignacio, Bruno Sangro, Thomas Yau, et al.. (2016). Safety and preliminary efficacy of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (aHCC): Interim analysis of the phase 1/2 CheckMate-040 study. Annals of Oncology. 27. vi209–vi209. 4 indexed citations

16.

Yap, Yoon Sim, K. L. Blackwell, David Cameron, et al.. (2016). LBA1 First-line ribociclib + letrozole in postmenopausal Asian women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): A subgroup analysis from MONALEESA-2. Annals of Oncology. 27(suppl_9). 7 indexed citations

17.

Paik, Jin Ho, Eui Kyu Chie, Seongjun Kim, et al.. (2015). Is c-Met oncoprotein expression an adverse prognosticator in extrahepatic bile duct cancer treated with curative resection followed by adjuvant chemoradiotherapy?. Clinical & Translational Oncology. 18(6). 625–631. 4 indexed citations

18.

Kim, Beom Seok, Dong Wook Kim, S.-A. Im, et al.. (2008). Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone. Annals of Oncology. 20(1). 121–128. 37 indexed citations

19.

Seo, Min‐Duk, K.-W. Lee, Hyeon Gyu Yi, et al.. (2008). Irinotecan Combined with 5-Fluorouracil and Leucovorin as Second-line Chemotherapy for Metastatic or Relapsed Gastric Cancer. Japanese Journal of Clinical Oncology. 38(9). 589–595. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact